AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04058743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TKA with nickel free components
Description: Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
Study NCT04058743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TKA with standard cobalt chromium components
Description: Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
Study NCT02535702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In vivo MRS
Description: 1H MR spectroscopy to assess brain metabolites.
Study NCT02189122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 162 mg
Description: Subjects will take aspirin 162 mg per day for 5 days.
Study NCT02189122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NHP544-C 81 mg
Description: Subjects will take NHP544C 81 mg per day for five days.
Study NCT02189122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NHP544C 162 mg
Description: Subjects will take NHP544C 162 mg once a day for five days.
Study NCT02189122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will take matching placebo for five days.
Study NCT00649142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open sutured mesh repair
Description: Open sutured mesh repair
Study NCT00649142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic mesh glue fixation
Description: Laparoscopic mesh glue fixation
Study NCT04896502 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Education
Description: Education regarding recognition and removal of in-home asthma triggers
Study NCT04896502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Video (IAV) Telemedicine
Description: Interactive video assessment of asthma triggers in the home.
Study NCT02292641 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery
Description: Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
Study NCT00581009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chronobiological augmentation
Description: Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days
Study NCT00581009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline, lithium
Description: Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.~Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks.
Study NCT00581009 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: one night of sleep deprivation and two FDG PET scans
Description: MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
Study NCT02535702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Three fMRI sessions to assess test-retest reliability of functional connectivity (FC) measures at rest and during task performance.
Study NCT02535702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG/EOG
Description: Electroencephalography or electrooculography (EEG/ EOG) sessions to record electrical activity of the brain or measure corneo-retinal standing potentials.
Study NCT02535702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation tasks
Description: To be used in the context of fMRI to study blood-oxygenation-level- dependent responses in the brain to sensory stimulation.
Study NCT02535702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NSPRD
Description: To be used in conjunction with pupillometry in the context of fMRI to study blood-oxygenation-level-dependent responses to selective neurostimulation of pain fibers.
Study NCT02535702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural MRI
Description: High spatial MRI and diffusion tensor imaging (DTI) to assess brain morphology and structural connectivity.
Study NCT01013792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound Dressing
Description: Acetate mesh carrier with ointment (water, PEGs)
Study NCT01013792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Dressing
Description: Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)
Study NCT04524273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inebilizumab
Description: Participants will receive IV inebilizumab
Study NCT04524273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: Participants will receive IV placebo matched to inebilizumab
Study NCT03191149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT03191149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography with Contrast
Description: Undergo CT with contrast
Study NCT03191149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03191149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03191149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT03191149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study NCT04440735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DSP107
Description: DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
Study NCT04440735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
Study NCT04606381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ami-LC-MD
Description: Participants will receive amivantamab admixed with rHuPH20 SC infusion.
Study NCT04606381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ami-LC
Description: Participants will receive amivantamab SC infusion.
Study NCT04606381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ami-HC
Description: Participants will receive amivantamab SC infusion.
Study NCT04606381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ami-HC-CF
Description: Participants will receive amivantamab co-formulated with rHuPH20 as SC infusion.
Study NCT04606381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Participants will receive lazertinib orally as a film-coated tablet.
Study NCT02839850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cementless Total Knee Arthroplasty
Description: Patients will undergo a primary total knee replacement using one of the two configurations of the ATTUNE Cementless knee (CR RP or PS RP)
Study NCT03424941 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI and TAVI
Description: Treatment of subjects with multivessel coronary artery disease and aortic stenosis for FFR-guided PCI and TAVI (Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO)
Study NCT03424941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CABG and SAVR
Description: Treatment of subjects with multivessel coronary artery disease and aortic stenosis for CABG and SAVR
Study NCT04378023 — intervention group
Intervention type: DRUG
Intervention: Neoadjuvant Chemo-radiotherapy
Description: Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
Study NCT04378023 — intervention group
Intervention type: PROCEDURE
Intervention: Liver Transplantation
Description: If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.
Study NCT04739072 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples
Study NCT04739072 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT05080114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Bakay technique (MT)
Description: The conventional standard technique for laparoscopic hysterectomy was followed until the colpotomy. The remaining steps were as follows: A 0-Monocryl™ violet (poliglecaprone-25) or a 0-PDS-II (polydioxanone) suture with a 36-mm needle (Ethicon Inc., NJ, USA) was placed first on the right USL, proximal to the ischial spine and 1-3 cm away from its uterine insertion, then helically proceeded by 1 to 3 bite(s) (depending on the length of the ligament) for suspension/plication. The suture continued circumferentially in counter clockwise direction on the line between the cervicovaginal junction and the bladder in a full-thickness purse string fashion, at least 1 cm away to the bladder. This suture symmetrically ended in the left USL, with forming nearly an Ohm sign (Ω). Colpotomy was performed circumferentially using laparoscopic cold scissors and/or knife, maintaining a safe distance from the suture line. Following removal of the uterus, both ends of the prior suture line were knotted.
Study NCT05080114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique (ST)
Description: The conventional standard total laparoscopic hysterectomy technique was used in this control group.~All operations were performed under general anaesthesia with nasogastric intubation and a bladder catheter in place. Cefazolin 2 g was administered to all patients for prophylaxis 30 min prior to surgery. Operations were performed with a 10-mm laparoscope (Karl Storz, Germany) through the trocar placed usually in the umbilicus. Two lateral 5-mm trocars and one midline 10-mm trocar were used. The placement of trocars varied according to the uterine size. Haemostasis was usually performed using bipolar forceps (Karl Storz Robi, Germany), whereas dissection was performed using the LigaSure™ (Covidien, Medtronic, USA). Maryland jaw laparoscopic sealer/divider, bipolar forceps and scissors. Colpotomy was performed with electrocautery devices and sutured intracorporeally.
Study NCT02828046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M281
Study NCT02828046 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03972657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5678
Description: Administered at the assigned dose level (DL) by intravenous (IV) infusion or subcutaneous (SC) administration
Study NCT03972657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered at the assigned DL by IV
Study NCT04349462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VideoFlurosocopy Swallow Study
Description: VFSS is a radiological examination that can identify the presence, nature and severity of any abnormalities in oropharyngeal, laryngeal and upper esophageal swallow physiology. The VFSS will be administered via a standardized protocol by a registered speech-language pathologist (SLP). During the VFSS, the patient is seated upright and swallows a variety of consistencies (eg. liquids, semisolids and solids) and volumes of barium-coated foods. A dynamic fluoroscopic image will be digitally captured and recorded.
Study NCT04349462 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Water Sip Test
Description: The steps of the water sip test include; 1. The patient will be given 5 ml of water, and if tolerated 20 ml followed by 50 ml of water (thin fluid) and the patient is assessed for cough/chocking during or after swallowing, wet or weak cough after swallowing. 2. The patient is asked to produce sustained vowel /a/ before and after swallowing of water and voice change after swallowing will be observed and recorded.
Study NCT03807219 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnox Comfort
Description: Magnox Comfort (Magnesium (226 mg in equivalent), Vitamin E - 45 mg, Vitamin B6 - 2 mg.).
Study NCT03807219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04538547 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Radiotherapy
Description: Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday
Study NCT04538547 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Non Accelerated Radiotherapy
Description: Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday
Study NCT03424018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 111
Description: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Study NCT01965379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restriction on food containing phosphorus additives
Description: The substitution of foods containing phosphorus additives for others with the same nutritional value for each individual of the study.
Study NCT01965379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: The control group mantained the usual renal diet oriented prior to the study with a booklet.
Study NCT01704469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The local anesthetic injection
Study NCT02354014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline (TMC207)
Description: TMC207 oral tablet adult formulation (containing 100 mg TMC207 per tablet) administered as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 200 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 1. Cohort 2, 3 and 4 will receive an age appropriate oral tablet formulation containing 20mg TMC207. Bedaquiline (TMC207) tablet administered orally as 200 mg, once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 100 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 2. In Cohort 3, dose of TMC207 8 mg/kg qd for the first 2 weeks, followed by TMC207 4 mg/kg tiw with intakes at least 2 days (48 hours) apart for 22 weeks will be administered. In cohort 4, TMC207 dose will be selected based on the results from the previous cohorts 1, 2 and 3.
Study NCT02354014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Regimen (BR)
Description: Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
Study NCT04557059 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Participants will receive radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), which will start within 4 weeks after randomization.
Study NCT04557059 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Participants will receive radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), which will start within 4 weeks after randomization.
Study NCT04557059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRHa
Description: Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization.
Study NCT04557059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRHa
Description: Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization.
Study NCT04557059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive therapeutic dose of apalutamide 240 mg once daily for 180 Days.
Study NCT00295893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV
Study NCT00295893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00295893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Given IV
Study NCT00295893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00295893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00295893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT00295893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00295893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02401074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Segmental Bronchoprovocation with Allergen (SBP-Ag)
Description: Premedication will consist of intramuscular glycopyrolate (0.2 mg), and midazolam (0.5-2.0 mg). Subjects will also be given a short-acting beta agonist, albuterol (2 puffs, 180 mcg) prior to bronchoscopy. Following nasopharyngeal anesthesia (topical lidocaine), the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During the SBP-Ag challenge, approximately 15% of the Ag-PD20 allergenic extract will be instilled into the segment (5)
Study NCT02043691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Custom Aortic Endograft
Description: The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
Study NCT02043691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith t-Branch Endovascular Graft
Description: The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
Study NCT02043691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgeon-Modified Endograft
Description: The Surgeon-Modified Endografts are created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
Study NCT03123289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Gallium citrate PET/CT scan
Description: After establishment of an intravenous access, approximately 5 mCi of 68Ga-citrate (Zevacor Molecular, Somerset, NJ, USA) will be administered intravenously. Whole body PET/CT scan will be performed after 60 minutes of uptake phase.
Study NCT03123289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F FDG PET/CT scan
Description: Subjects will undergo FDG PET/CT scan using the same imaging parameters either on the same day or within the next 24-48 hours. The subjects will be requested to fast for a minimum of 4 h prior to PET acquisition. After confirmation of a blood glucose level ≤200 mg/dl, technologists will establish the intravenous access and the subject will receive approximately 10 mCi of 18F-FDG (Zevacor Molecular, Somerset, NJ, USA) intravenously. The subject will be placed in uptake room for 60 minutes to allow for optimal localization of the compound. The subjects will be requested to void prior to administration of 18FDG and again prior to image acquisition.
Study NCT00321048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Breathing Coordinator
Description: A SPECT scan will be used to determine if the active breathing device reduces radiation toxicities.
Study NCT03538483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: 30 ml %0,25 bupivacaine
Study NCT03538483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl Inj 0.25%
Description: 20 ml %0,25 bupivacaine